Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

Aim: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an ‘early adjustment prescribing scenario’. Methods: An economic model was constructed to com...

Full description

Bibliographic Details
Main Authors: Jaesh Naik, Ryan Dillon, Matthew Massello, Lewis Ralph, Zhuo Yang
Format: Article
Language:English
Published: Becaris Publishing Limited 2023-01-01
Series:Journal of Comparative Effectiveness Research
Subjects:
antimicrobial resistance
cost–effectiveness analysis
culture and susceptibility
habp/vabp
health economics
imipenem/cilastatin/relebactam
infectious diseases

Similar Items